文献速递创伤与烧伤消化、代谢与肾脏急症

鼻内舒芬太尼对急诊科急性创伤后疼痛的影响:一项随机对照试验

Effect of intranasal sufentanil on acute post-traumatic pain in the emergency department: a randomised controlled trial.
PubMed 文献 · Emerg Med J · 2024-01-22
一句话结论急诊严重创伤疼痛(VAS≥7)患者中,鼻内舒芬太尼联合非阿片镇痛比口服/静脉阿片类更能减痛,但不良反应更常见。

这项单中心、开放标签、平行组、随机对照优效性试验于2020年1月至2022年2月纳入急诊创伤、VAS评分≥7的患者,随机接受鼻内舒芬太尼或口服/静脉其他阿片类药物,均联合口服/静脉对乙酰氨基酚和非甾体抗炎药。意向性分析纳入170例(舒芬太尼组83例,口服/静脉阿片组87例)。随机化后15-20分钟VAS减分鼻内舒芬太尼组3.0(IQR 1.7-5.0)vs 口服/静脉阿片组1.5(IQR 0.9-3.0),p<0.001;60分钟减分5.0(IQR 3.0-7.0)vs 3.0(IQR 2.0-5.3),p<0.001。但干预组不良反应更常见(71.1% vs 23%;p<0.001)。作者认为鼻内舒芬太尼可考虑用于严重创伤疼痛的管理。

要点

  • 急诊创伤VAS≥7患者,鼻内舒芬太尼联合对乙酰氨基酚和非甾体抗炎药,15-20分钟VAS减分3.0(IQR 1.7-5.0),高于口服/静脉阿片组的1.5(IQR 0.9-3.0),p<0.001。
  • 60分钟VAS减分鼻内舒芬太尼组5.0(IQR 3.0-7.0),口服/静脉阿片组3.0(IQR 2.0-5.3),p<0.001。
  • 不良反应发生率鼻内舒芬太尼组71.1%,口服/静脉阿片组23%,p<0.001,用药后需关注不良反应。
  • 作者认为,鼻内舒芬太尼可考虑用于严重创伤疼痛患者的管理。

适用人群与场景

  • 急诊科创伤患者,疼痛视觉模拟量表(VAS)评分≥7分。

诊断标准与关键阈值

  • 疼痛评分采用视觉模拟量表(VAS),纳入标准为评分≥7分。

处置流程与药物剂量

  • 鼻内舒芬太尼组接受鼻内舒芬太尼,并联合口服/静脉对乙酰氨基酚和非甾体抗炎药。
  • 对照组接受口服/静脉其他阿片类药物,并联合口服/静脉对乙酰氨基酚和非甾体抗炎药。
  • 作者认为,鼻内舒芬太尼可考虑用于严重创伤疼痛患者的管理。

研究设计与关键结果

  • 单中心、开放标签、平行组、随机对照优效性试验,2020年1月至2022年2月,筛查205例,意向性分析纳入170例。
  • 鼻内舒芬太尼组83例 vs 口服/静脉阿片组87例;随机化后15-20分钟VAS减分3.0(IQR 1.7-5.0)vs 1.5(IQR 0.9-3.0),p<0.001。
  • 随机化后60分钟VAS减分5.0(IQR 3.0-7.0)vs 3.0(IQR 2.0-5.3),p<0.001。
  • 不良反应发生率鼻内舒芬太尼组71.1% vs 口服/静脉阿片组23%,p<0.001。

证据类型、等级与局限

  • 证据类型:随机对照试验(单中心、开放标签、平行组、优效性设计)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于急诊创伤后VAS≥7分的患者,在联合对乙酰氨基酚和非甾体抗炎药的基础上,鼻内舒芬太尼可比口服/静脉阿片类药物带来更大的15-20分钟和60分钟VAS减分,但不良反应更常见(71.1% vs 23%)。
  • 作者认为,鼻内舒芬太尼可考虑用于严重创伤疼痛患者的管理。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Intranasal sufentanil is a potent opioid which can be used in patients with traumatic injuries presenting to the ED. Although previous studies have demonstrated the superiority of intranasal sufentanil over intravenous morphine in terms of pain relief, its clinical superiority in patients with traumatic injuries receiving adequate multimodal analgesia with acetaminophen and non-steroidal anti-inflammatory drugs is uncertain. We compared pain relief offered by intranasal sufentanil with that offered by oral and intravenous opioids in patients with acute traumatic injuries also receiving a specified regimen of non-opioid treatment.

METHODS: In this single-centre, open-label, parallel-group, randomised controlled superiority trial conducted between January 2020 and February 2022, trauma patients presenting to the ED with a pain score of ≥7 on a visual analogue scale (VAS) were randomised to receive either intranasal sufentanil or other oral/intravenous opioids alongside oral/intravenous acetaminophen and non-steroidal anti-inflammatory drugs. The primary outcome was reduction in VAS score 15-20 min after randomisation.

RESULTS: An intention-to-treat analysis included 170 out of 205 patients screened for inclusion. The intranasal sufentanil group (83 patients) showed a significantly greater reduction in pain when compared with the oral/intravenous opioid group (87 patients) 15-20 min after randomisation (reduction in VAS score 3.0 (IQR 1.7-5.0) vs 1.5 (IQR 0.9-3.0); p<0.001). Similarly, a greater reduction in pain was observed in the intranasal sufentanil group 60 min after randomisation (5.0 (IQR 3.0-7.0) vs 3.0 (IQR 2.0-5.3); p<0.001). However, side effects were more frequent in the intervention group (71.1% vs 23%; p<0.001).

CONCLUSIONS: Intranasal sufentanil was associated with more effective pain relief than oral/intravenous opioids in patients with traumatic injuries treated with coanalgesia. Intranasal sufentanil could be considered for the management of pain in patients with traumatic injuries associated with severe pain.

TRIAL REGISTRATION NUMBER: NCT04137198.

来源:Emerg Med J,查看原文。版权归原作者所有。

参考来源

  1. Malinverni S, Kreps B, Lucaccioni T, et al. Effect of intranasal sufentanil on acute post-traumatic pain in the emergency department: a randomised controlled trial. Emerg Med J. 2024. PMID: 37770120. doi:10.1136/emermed-2023-213353

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。